{"id":22197,"date":"2024-10-23T11:41:30","date_gmt":"2024-10-23T11:41:30","guid":{"rendered":"https:\/\/clinlabint.com\/?p=22197"},"modified":"2024-10-23T11:41:30","modified_gmt":"2024-10-23T11:41:30","slug":"exothera-appoints-new-ceo-to-lead-viral-vector-and-nucleic-acid-production","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/exothera-appoints-new-ceo-to-lead-viral-vector-and-nucleic-acid-production\/","title":{"rendered":"Exothera appoints new CEO to lead viral vector and nucleic acid production"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Exothera appoints new CEO to lead viral vector and nucleic acid production<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Exothera, a GMP-certified contract development and manufacturing organisation (CDMO) specialising in viral vectors, RNA therapeutics, and vaccines, has announced the appointment of C\u00e9dric Volanti as its new Chief Executive Officer. The appointment, effective 8 October 2024, marks a significant milestone for the Belgian company as it seeks to strengthen its position in the biopharmaceutical manufacturing sector.<\/h3>\n

<\/p>\n

Volanti\u2019s background and expertise<\/h4>\n

Volanti brings a wealth of experience to his new role at Exothera. Holding a PhD in molecular and cellular biology from the University of Li\u00e8ge, Volanti\u2019s academic background includes two postdoctoral fellowships at Harvard Medical School, focusing on virology and immunology. His scientific expertise is complemented by a master\u2019s degree in management, which he obtained in the late 2000s.<\/p>\n

Volanti\u2019s professional trajectory spans several executive positions in the cell and gene therapy sector across Europe and North America. His previous roles include leadership positions at SGS in Switzerland and Belgium, PharmaCell in the Netherlands, Delphi Genetics in Belgium, and Novasep in France. Most recently, Volanti served as Vice President & General Manager of Viral Vector Services at Thermo Fisher Scientific in the United States.<\/p>\n

Strategic vision for Exothera<\/h4>\n

As the newly appointed CEO, Volanti is tasked with defining and implementing Exothera\u2019s global strategy. This comes at a crucial juncture for the company, which was founded just four years ago. The focus of this strategic direction will be threefold: driving innovation, expanding international presence, and developing new products and services.<\/p>\n

Volanti\u2019s appointment aligns with Exothera\u2019s objectives to capitalise on emerging technologies and maintain a competitive edge in the rapidly evolving field of advanced therapies. His international experience and dynamic approach are expected to play a pivotal role in shaping the company\u2019s future trajectory.<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

Exothera\u2019s capabilities and market position<\/h4>\n

Founded in 2020, Exothera has quickly established itself as a key player in the CDMO landscape, particularly in the realm of viral vector and nucleic acid production. The company offers a comprehensive range of services spanning from early discovery to commercial cGMP manufacturing, catering to the pharmaceutical industry\u2019s needs in developing advanced therapies.<\/p>\n

Exothera\u2019s expertise lies in leveraging cutting-edge bioprocessing technologies to optimise the production of vaccines, viral vectors, oncolytic viruses, and nucleic acids. This technological prowess, combined with the company\u2019s GMP-certified status, positions Exothera as a valuable partner for biopharmaceutical companies seeking to advance their pipeline of advanced therapy medicinal products (ATMPs).<\/p>\n

Challenges and opportunities in the CDMO sector<\/h4>\n

The appointment of Volanti comes at a time when the CDMO sector, particularly in the field of cell and gene therapies, is experiencing significant growth and transformation. The increasing pipeline of advanced therapy candidates has created a surge in demand for specialised manufacturing capabilities, presenting both challenges and opportunities for companies like Exothera.<\/p>\n

One of the key challenges facing CDMOs in this space is the need to continually innovate and adapt to new technologies while maintaining regulatory compliance and cost-effectiveness. Volanti\u2019s experience across multiple organisations in the sector is likely to prove valuable in navigating these complex demands.<\/p>\n<\/div><\/section>
\n